### Saturday, August 30, 2014

#### Special Session
**“Message from Fukushima”**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:10 - 8:55 | **Special Lecture 02**  
**Moderator:** Keizo Sugimachi (Onga Hospital)  
**SL2-1** | **Scope for the future of Fukushima; resilience creation after the nuclear accident**  
*Nagasaki University*  
*Shunichi Yamashita* |
| 9:00 - 9:50 | **Special Lecture 03**  
**Moderator:** Tetsuichiro Muto (Cancer Institute Hospital of JFCR)  
**SL3-1** | **The Anne Frank House in Amsterdam as a Memorial Site: Five Decades of Active Learning Methodology in International Practice**  
*MA, Anne Frank House, Amsterdam, The Netherland*  
*Jan Erik Dubbelman*  
**SL3-2** | **History, memory and trauma: Holocaust survivor testimonies and the potential of oral history**  
*VU University Amsterdam, The Netherland*  
*Dienke Hondius* |
| 10:00 - 12:00 | **Special Session 01**  
**Nuclear Disaster and Health: Evidence from Fukushima**  
**Commentators:** Masafumi Abe (Fukushima Medical University)  
Hitoshi Ohto (Fukushima Medical University)  
**SS2-1** | **Measurement of internal radiation exposure of Fukushima residents after the Great East Japan Earthquake by Whole Body Counter**  
*Department of Radiation Health Management, Fukushima Medical University*  
*Makoto Miyazaki*  
**SS2-2** | **Measurement of Internal Exposure Doses with Meals by Duplicate Diet Method**  
*Department of Welfare, Fukushima College*  
*Osamu Sato*  
**SS2-3** | **Radioactive Substances in tap water**  
*Food Safety & Environmental Hygiene Division, Social Health & Welfare Department, Fukushima Prefecture*  
*Ryo Atsumi*  
**SS2-4** | **Radiation exposure and thyroid ultrasound examination from the data of the Fukushima Health Management Survey**  
*Dept. of Thyroid and Endocrinology, Fukushima Medical University*  
*Shinichi Suzuki*  
**SS2-5** | **Pregnancy and birth survey in Fukushima after radiation disaster**  
*Department of Obstetrics and Gynecology, School of Medicine, Fukushima Medical University*  
*Keiya Fujimori*  
**SS2-6** | **Changes in health status among residents after the Great East Japan Earthquake: the Fukushima Health Management Survey**  
*Department of Epidemiology, School of Medicine, Fukushima Medical University*  
*Tetsuya Ohira* |
SS2-7 Mental health problems of the evacuees disclosed by Fukushima Health Management Survey
Department of Neuropsychiatry, Fukushima Medical University
Hirooki Yabe

13:30 - 16:00

Special Session 03
Movie : Hameln (Japanese Only)

Room 02 (Conference Center, 3F, 301+302)
Organ Specific Symposium 17
Up-to-Date Breast Cancer Treatment
-New Strategies in the Treatment of HER2 Positive Diseases-
Moderators: Masakazu Toi (Breast Surgery, Kyoto University Hospital)
Tohru Ohtake (Department of Regulatory Surgery, Fukushima Medical University)

OS17-1 Updates on Development of anti-HER2 treatment
Stanford Cancer Institute, Stanford University School of Medicine, U.S.A.
Mark D. Pegram

OS17-2 New development of treatment for HER2-positive metastatic breast cancer
Breast Medical Oncology, The Cancer Institute Hospital
Yoshinori Ito

OS17-3 Novel treatment strategies for HER2-positive breast cancers
Division of Breast and Endocrine, Department of Surgery, Hyogo College Of Medicine
Yasuo Miyoshi

OS17-4 Current status and future perspective in primary systemic therapy for HER2-positive breast cancer patients
Surgery, Breast Oncology, Osaka Medical Center, National Hospital Organization
Norikazu Masuda

OS17-5 New treatment strategy for HER2 positive breast cancer
Aichi Cancer Center Hospital and Research Institute
Hiroji Iwata

OS17-6 Treatment strategy for Luminal-HER2 and HER2-enriched breast cancer based on biological characteristics
Division of Breast Oncology, National Hospital Organization Kyushu Cancer Center
Shinji Ohno

Room 03 (Conference Center, 3F, 303+304)
Symposium 13
The Current Situations and Issues of Clinical Researches in Japan for Recovering of Trust
Moderators: Yasuhiro Fujiwara (Strategic and Planning Bureau, National Cancer Center)
Kazuhiko Yoshida (Department of Surgical Oncology, Gifu University)

S13-1 New Framework for Promoting Medical Research and Development
Office of Healthcare Policy, Cabinet Secretariat

S13-2 Measures taken by Ministry of Health, Labour and Welfare - Revision of the Ethical Guidelines for Clinical Studies and the situation revolving around clinical study
Health Policy Bureau Research and Development Division, Office of Clinical Trial Promotion,
Ministry of Health, Labour and Welfare
Yuta Ogawa

S13-3 Legal Regulation for the Clinical Research in the Context of Global Trends
Law School, Keio University
Tetsu Isobe
S13-4  Changing policies on human research protections in Japan  
Office for Promoting Medical Research, Showa University  
Shimon Tashiro

Room 03 (Conference Center, 3F, 303+304)  
10:00 - 12:00  
Plenary Session

Moderator:  Seiichiro Ozono  (Urology, Hamamatsu University School of Medicine)

PS-1  Upper urinary tract recurrence following intravesical BCG therapy for non-muscle invasive bladder cancer: a multi-institutional retrospective study  
Department of Urology, Hospital, Sapporo Medical University  
Naotaka Nishiyama

PS-2  Male infertility treatment after cancer  
Urology, Graduate School of Medicine, Yamaguchi University  
Koji Shiraishi

Moderator:  Eigo Otsuji  (Digestive Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)

PS-3  Current status and future perspective of sentinel node navigation surgery in gastric cancer  
Department of Surgery, School of Medicine, Keio University  
Hiroya Takeuchi

PS-4  A randomized phase III trial of mFOLFOX6+bevacizumab vs. FOLFIRI+bevacizumab for metastatic colorectal cancer: WJOG4407G  
Department of Medical Oncology, Nara Hospital Kinki University  
Takao Tamura

Moderator:  Hiroyuki Kuwano  (General Surgical Science, Graduate School of Medicine, Gunma University)

PS-5  Improved Postoperative Prognosis of Pancreatic Cancer with Para-aortic Lymph Node Metastasis: A Multicenter Study on 822 Patients  
Surgery, Nara Medical University  
Masayuki Sho

PS-6  A randomized phase III study of cisplatin etoposide and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer: JCOG0605  
National Cancer Center Hospital  
Noboru Yamamoto

Moderator:  Hidetaka Katabuchi  (Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University)

PS-7  Efficacy and safety of anti-PD-1 antibody (Nivolumab : BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer  
Obstetrics and Gynecology, Hospital, Kyoto University  
Junzo Hamanishi

Moderator:  Takaumi Ueda  (Dept of Orthopaedic Surgery, Osaka Medical Center, National Hospital Organization)

PS-8  Circulating miR-206 as a novel prognostic biomarker for rhabdomyosarcoma  
Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine  
Mitsuru Miyachi
Room 06 (Conference Center, 3F, 315) 8:00 - 10:00

**International Symposium 06 (Princess Takamatsu Cancer Research Fund Sponsored)**

**The Future of Cancer Therapy**

*Checkpoint Immunotherapy by Checkpoint Blockade*

**Moderators:**

- **Yutaka Kawakami** (Institute for Advanced Medical Research Division of Cellular Signaling, School of Medicine, Keio University)
- **Hiroshi Shiku** (Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine)

**TIS6-1**

**A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application**

*Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University*

Tasuku Honjo

**TIS6-2**

**Cancer Immunotherapy by Checkpoint Blockade**

*Department of Medical and Molecular Pharmacology, Department of Medicine, Division of Hematology / Oncology, University of California Los Angeles (UCLA), and the Jonsson Comprehensive Cancer Center at UCLA, U.S.A.*

Antoni Ribas

**TIS6-3**

**Blocking the PD-1 / PD-L1 Interaction to Treat Cancer**

*Immunology, Oncology and Urology, Johns Hopkins Kimmel Cancer Center, U.S.A.*

Charles G. Drake

**TIS6-4**

**Checkpoint blockade-based combination therapies against cancer**

*Department of Immunology, Graduate School of Medicine, Yamaguchi University*

Koji Tamada

---

Room 07 (Conference Center, 4F, 413) 8:00 - 10:00

**Symposium 14**

**Cancer Education at School**

**Moderators:**

- **Keiichi Nakagawa** (Department of Radiology, Hospital, The University of Tokyo)
- **Izumi Nakamura** (Department of Regulatory Surgery, Fukushima Medical University)

**S14-1**

**Outlook and practice of cancer education**

*Radiology, Hospital, The University of Tokyo*

Keiichi Nakagawa

**S14-2**

**Efforts report - from 2010 - the cancer education cancer patients tell**

*Nonprofit Organization Gan Support Kagoshima*

Aya Miyoshi

**S14-3**

**The measures of cancer education in Kanagawa Prefecture**

*Cancer Division, Kanagawa Prefectural Government*

Yoko Nakazawa

**S14-4**

**JCS efforts for cancer class**

*Project Proposal, Japan Cancer Society*

Rie Anami

**S14-5**

**A Prospect of “Cancer Education” in Japan**

*Director, School Health Education Division, Ministry of Education, Culture, Sports, Science and Technology*

Masahiro Oji

---

Room 10 (Conference Center, 4F, 418) 8:00 - 8:30

**Keynote Lecture 08**

**Moderator:**

**Keichi Hagiwara** (Department of Respiratory Medicine, Saitama Medical University)

**KL8-1**

**Secretoglobin (SCGB) 3A2 is a novel anti-tumor agent**

*Endocrinology Section, Laboratory of Metabolism, National Cancer Institute, U.S.A.*

Shioko Kimura
Room 10 (Conference Center, 4F, 418) 8:30 - 9:20

International Session 2

Anti Cancer Agent

Moderators: Osamu Ogawa (Department of Urology, Faculty of Medicine, Kyoto University)  
Mitsuo Shimada (Department of Surgery, Graduate School, The University of Tokushima)

ISO2-1 ER alpha regulates Epithelial-mesenchymal transition in breast cancers through suppressing Bmi1 expression  
The Breast Center, The Affiliated Cancer Hospital of Shantou University Medical College, China  
Guo-jun Zhang

ISO2-2 Monocyte Chemoattractant Protein-1 Modulates Invasion and Apoptosis of PC-3M Prostate Cancer Cells Via Regulating Expression of VEGF, MMP9 and Caspase-3  
Urology, FAW General Hospital, China  
Chaoling Shi

ISO2-3 Results of the first-in-human phase I trial assessing the oral selective c-Met inhibitor MSC2156119J (EMD 1214063) in patients with advanced solid tumors  
Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), MD Anderson Cancer Center, U.S.A.  
Gerald S. Falchook

ISO2-4 Ubiquitin Ligase Inhibitor is an Effective Combination Therapy with Radiation in Hypoxic Colorectal Cancer Cells  
Radiation Oncology, Graduate School, Gunma University  
Navchaa Gombodorj

ISO2-5 A novel anti-cancer agent of DNA-alkylating Pyrrole-Imidazole polyamide conjugate targeting KRAS Codon 12 Mutant DNA  
Cancer Genetics, Chiba Cancer Center  
Hiroki Nagase

ISO2-6 Implication of IRSp53 in cell proliferation by interaction with p107 via NPY motif  
Molecular Medicine Cell Biology Lab, Graduate School of Biological Sciences, NAIST, Japan  
Fatemeh Safari

Room 12 (Conference Center, 5F, 501) 8:00 - 10:00

Organ Specific Symposium 18

Up-to-Date Liver Cancer Treatment

Moderators: Go Wakabayashi (Surgery, Iwate Medical University)  
Hiroaki Nagano (Department of Surgery and Transplant Medicine, Graduate School, Osaka University)

OS18-1 Hepatectomy for colorectal liver metastases after chemotherapy  
Department of Gastroenterological Surgery, Aichi Cancer Center Hospital  
Yoshiki Senda

OS18-2 Possible prevention of the development and recurrence of hepatocellular carcinoma by antiviral therapy for persistent hepatitis B or C viral infection  
Department of Hepatology, Graduate School of Medicine, Osaka City University  
Norifumi Kawada

OS18-3 Comparison of the efficacy of sorafenib and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma  
Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University  
Makoto Chuma

OS18-4 The goal of multidisciplinary treatment for advanced hepatocellular carcinoma  
Department of Surgery, Graduate School of Medicine, Kyoto University  
Etsuro Hatano

OS18-5 Current status and future of liver transplantation  
Division of Transplant Surgery, Department of Surgery, School of Medicine, Shinshu University  
Toshihiko Ikegami

OS18-6 The 3rd version of Clinical Practice Guidelines for Hepatocellular Carcinoma: revision procedures and current problems  
Hepato-Biliary-Pancreatic Surgery Division, Graduate School of Medicine, The University of Tokyo  
Kiyoshi Hasegawa
### Room 13 (Conference Center, 5F, 502)
8:00 - 10:20

**Organ Specific Symposium 19**

**Up-to-Date Head and Neck Cancer Treatment**

**Moderators:**  
Tadaaki Kirita (Department of Oral and Maxillofacial Surgery, Nara Medical University)  
Kenichi Nibu (Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kobe University)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Affiliation</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>OS19-1</td>
<td>Treatment strategy for oral cancer, up to date</td>
<td>Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University</td>
<td>Ken Omura</td>
</tr>
<tr>
<td>OS19-2</td>
<td>Functional unit reconstruction after oral oncologic surgery</td>
<td>Department of Stomatology and Maxillofacial, Graduate School of Medicine, Gunma University</td>
<td>Satoshi Yokoo</td>
</tr>
<tr>
<td>OS19-3</td>
<td>Nasopharyngeal carcinoma -Treatment concept according to EBV status-</td>
<td>Otolaryngology-Head and Neck Surgery, Kanazawa University</td>
<td>Tomokazu Yoshizaki</td>
</tr>
<tr>
<td>OS19-4</td>
<td>Human Papillomavirus and Cystic Node Metastasis in Oropharyngeal Cancer and Cancer of Unknown Primary</td>
<td>Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Osaka University</td>
<td>Hidenori Inohara</td>
</tr>
<tr>
<td>OS19-5</td>
<td>Flexible endoscopic transoral surgery using a curved distending laryngoscope in patients with early-stage hypopharyngeal cancer</td>
<td>Otolaryngology, Tokyo Medical and Dental University</td>
<td>Taro Sugimoto</td>
</tr>
<tr>
<td>OS19-6</td>
<td>Molecular-targeted agent</td>
<td>School of Medicine, Department of Oto-Rhino-Laryngology, The Jikei University</td>
<td>Susumu Okano</td>
</tr>
</tbody>
</table>

### Room 14 (Conference Center, 5F, 503)
8:00 - 10:00

**Organ Specific Symposium 20**

**Up-to-Date Endometrial Cancer Treatment**

**Moderators:**  
Tsutomu Tabata (Obstetrics and Gynecology, Faculty of Medicine, Mie University)  
Nobuhiro Takeshima (Gynecology, The Cancer Institute Hospital)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Affiliation</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>OS20-1</td>
<td>Limited resection for endometrial cancer</td>
<td>Department of Obstetrics and Gynecology, Mie University Hospital</td>
<td>Takashi Motohashi</td>
</tr>
<tr>
<td>OS20-2</td>
<td>Tailoring lymphadenectomy in the surgical management of endometrial cancer</td>
<td>Gynecology, Hokkaido University Hospital</td>
<td>Hidemichi Watari</td>
</tr>
<tr>
<td>OS20-3</td>
<td>How to safely perform a laparoscopic surgery for endometrial cancer</td>
<td>Kurashiki Medical Center</td>
<td>Hiroyuki Kanao</td>
</tr>
<tr>
<td>OS20-4</td>
<td>Sentinel Lymph Node in Endometrial Cancer</td>
<td>Obstetrics and Gynecology, Osaka Medical College</td>
<td>Yoshito Terai</td>
</tr>
<tr>
<td>OS20-5</td>
<td>Adjuvant treatment for uterine corpus cancer</td>
<td>Obstetrics &amp; Gynecology, Faculty of Medicine, Tottori University</td>
<td>Muneaki Shimada</td>
</tr>
<tr>
<td>OS20-6</td>
<td>Platinum-free interval (PFI) in second-line chemotherapy for recurrent endometrial cancer</td>
<td>The Cancer Institute Hospital</td>
<td>Maki Matoda</td>
</tr>
</tbody>
</table>